MGTX vs. CRBU, BDTX, TNYA, JSPR, CADL, SOPH, AVXL, TRML, IVVD, and AURA
Should you be buying MeiraGTx stock or one of its competitors? The main competitors of MeiraGTx include Caribou Biosciences (CRBU), Black Diamond Therapeutics (BDTX), Tenaya Therapeutics (TNYA), Jasper Therapeutics (JSPR), Candel Therapeutics (CADL), SOPHiA GENETICS (SOPH), Anavex Life Sciences (AVXL), Tourmaline Bio (TRML), Invivyd (IVVD), and Aura Biosciences (AURA). These companies are all part of the "biological products, except diagnostic" industry.
MeiraGTx (NASDAQ:MGTX) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, community ranking, media sentiment, institutional ownership and valuation.
In the previous week, Caribou Biosciences had 7 more articles in the media than MeiraGTx. MarketBeat recorded 8 mentions for Caribou Biosciences and 1 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.80 beat Caribou Biosciences' score of 0.28 indicating that MeiraGTx is being referred to more favorably in the media.
MeiraGTx has higher earnings, but lower revenue than Caribou Biosciences. MeiraGTx is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.
MeiraGTx currently has a consensus price target of $26.00, suggesting a potential upside of 356.94%. Caribou Biosciences has a consensus price target of $21.50, suggesting a potential upside of 589.10%. Given Caribou Biosciences' higher probable upside, analysts clearly believe Caribou Biosciences is more favorable than MeiraGTx.
MeiraGTx has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.56, suggesting that its share price is 156% more volatile than the S&P 500.
MeiraGTx received 170 more outperform votes than Caribou Biosciences when rated by MarketBeat users. Likewise, 71.10% of users gave MeiraGTx an outperform vote while only 53.13% of users gave Caribou Biosciences an outperform vote.
67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 9.7% of MeiraGTx shares are owned by company insiders. Comparatively, 9.5% of Caribou Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Caribou Biosciences has a net margin of -345.05% compared to MeiraGTx's net margin of -651.19%. Caribou Biosciences' return on equity of -33.42% beat MeiraGTx's return on equity.
Summary
Caribou Biosciences beats MeiraGTx on 10 of the 18 factors compared between the two stocks.
Get MeiraGTx News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MeiraGTx Competitors List
Related Companies and Tools
